Cost-effectiveness of long-acting insulin analogues versus intermediate/long-acting human insulin for type 1 diabetes: a population-based cohort following over 10 years.
This study assessed the cost-effectiveness of long-acting insulin analogues (LAIAs) versus intermediate/long-acting human insulin (ILAHI) for patients with type 1 diabetes (T1D) in real-world clinical practice. Individual-level analyses were conducted within a longitudinal population-based cohort of 540 propensity score-matched T1D patients (LAIAs, n=270; ILAHI, n=270) with over 10 years of follow-up using Taiwan's National Health Insurance Research Database, 2004-2013, from third-party payer and healthcare sector perspectives. The study outcomes included the number needed to treat (NNT) to prevent one case of clinical events (e.g., hypoglycemia, diabetes-related complications [DRCs]), medical costs, and cost per case of events prevented. Cost estimates are presented in 2013 British Pounds (GBP, £). The NNT of using LAIAs versus ILAHI to avoid one case of hypoglycemia requiring medical assistance, outpatient hypoglycemia, and any DRCs was 12, 9, and 10 for a mean follow-up period of 5.84, 6.02, and 3.62 years, respectively. From third-party payer and healthcare sector perspectives, using LAIAs instead of ILAHI saved GBP6,924-GBP7,116 per case of hypoglycemia requiring medical assistance prevented, GBP5,346-GBP5,508 per case of outpatient hypoglycemia prevented, and GBP3,570-GBP3,680 per case of any DRCs prevented. Sensitivity analyses considering sampling uncertainty showed that using LAIAs over ILAHI yields at least a 76% probability of being cost-saving for avoiding one case of hypoglycemia requiring medical assistance, outpatient hypoglycemia, or any DRCs. This real-world evidence reveals that compared with ILAHI, the greater pharmaceutical costs associated with LAIAs for patients with T1D could be substantially offset by savings from averted hypoglycemia or DRCs.